← Leaderboards
Philip W Kantoff
Dana-Farber Cancer Institute
$10,106,399
Attributed
$10,779,345
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$42,276,417 · 13
By mechanism
P50$38,027,244 · 8
P01$2,449,678 · 3
U01$1,345,893 · 1
P30$453,602 · 1
Top collaborators
- James L. Gulley3 shared
- Mark M. Pomerantz1 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Phillip G Febbo$3,708,103
- Thomas S. Kupper$36,607,647
- Myles A Brown$19,328,495
- Othon Iliopoulos$11,620,320
- William G Kaelin$28,163,102
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateProgramsResearch PersonnelFundingDana-Farber Cancer InstituteEvaluationBaseSuccessInstitutionReportingCancer CenterEnsureGrantCareer DevelopmentScientistCollaborationsMentorsTechnologyFutureMemberCommunitiesDecision MakingPhysiciansComplement
Grant awards (61)
Administrative Core$89,224
P01 · FY2024 · CA · contact PI
Administrative Core$99,438
P01 · FY2023 · CA · contact PI
Administrative Core$99,438
P01 · FY2022 · CA · contact PI
Administrative Core$112,219
P01 · FY2021 · CA · contact PI
The Impact of DNA Damage Repair Abnormalities in Prostate Cancer$1,929,187
P01 · FY2019 · CA · contact PI
Administrative Core$120,172
P01 · FY2019 · CA · contact PI
Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer$416,435
U01 · FY2018 · CA · contact PI
Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer$458,934
U01 · FY2017 · CA · contact PI
Administrative Core$284,486
P50 · FY2017 · CA · contact PI
Career Development Program$151,978
P50 · FY2017 · CA · contact PI
Developmental Research Program$151,978
P50 · FY2017 · CA · contact PI
Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer$470,524
U01 · FY2016 · CA · contact PI
Administrative Core$260,573
P50 · FY2016 · CA · contact PI
Developmental Research Program$171,204
P50 · FY2016 · CA · contact PI
Career Development Program$171,202
P50 · FY2016 · CA · contact PI
Prostate Cancer$93,226
P30 · FY2016 · CA · contact PI
Administrative Core$267,601
P50 · FY2015 · CA · contact PI
Developmental Research Program$170,823
P50 · FY2015 · CA · contact PI
Career Development Program$170,822
P50 · FY2015 · CA · contact PI
Prostate Cancer$93,259
P30 · FY2015 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,112,781
P50 · FY2014 · CA · contact PI
Administrative Core$282,570
P50 · FY2014 · CA · contact PI
Developmental Research Program$112,707
P50 · FY2014 · CA · contact PI
Career Development Program$112,706
P50 · FY2014 · CA · contact PI
Prostate Cancer$88,362
P30 · FY2014 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,150,500
P50 · FY2013 · CA · contact PI
Administrative Core$284,540
P50 · FY2013 · CA · contact PI
Developmental Research Program$168,522
P50 · FY2013 · CA · contact PI
Career Development Program$168,521
P50 · FY2013 · CA · contact PI
Prostate Cancer$85,514
P30 · FY2013 · CA · contact PI
Prostate Cancer$93,241
P30 · FY2012 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,185,000
P50 · FY2011 · CA · contact PI
Administration, Evaluation, and Planning Core$609,973
P50 · FY2011 · CA · contact PI
Career Development Program$173,860
P50 · FY2011 · CA · contact PI
Developmental Research Program$173,860
P50 · FY2011 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,300,000
P50 · FY2010 · CA · contact PI
Administration, Evaluation, and Planning Core$642,077
P50 · FY2010 · CA · contact PI
Career Development Program$183,011
P50 · FY2010 · CA · contact PI
Developmental Research Program$183,011
P50 · FY2010 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,463,000
P50 · FY2009 · CA · contact PI
Administration, Evaluation, and Planning Core$502,804
P50 · FY2009 · CA · contact PI
Molecular Signatures of Lethal an Indolent Prostate Cancer$398,681
P50 · FY2009 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$352,826
P50 · FY2009 · CA · contact PI
Career Development Program$143,309
P50 · FY2009 · CA · contact PI
Developmental Research Program$143,308
P50 · FY2009 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,463,000
P50 · FY2008 · CA · contact PI
Administration, Evaluation, and Planning Core$502,795
P50 · FY2008 · CA · contact PI
Molecular Signatures of Lethal an Indolent Prostate Cancer$398,676
P50 · FY2008 · CA · contact PI
Career Development Program$143,314
P50 · FY2008 · CA · contact PI
Developmental Research Program$143,313
P50 · FY2008 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,461,000
P50 · FY2007 · CA · contact PI
Administration, Evaluation, and Planning Core$502,387
P50 · FY2007 · CA · contact PI
Molecular Signatures of Lethal an Indolent Prostate Cancer$398,352
P50 · FY2007 · CA · contact PI
Career Development Program$143,198
P50 · FY2007 · CA · contact PI
Developmental Research Program$143,197
P50 · FY2007 · CA · contact PI
SPORE in Prostate Cancer$2,634,869
P50 · FY2006 · CA · contact PI
SPORE in Prostate Cancer$2,698,278
P50 · FY2005 · CA
SPORE in Prostate Cancer$2,534,537
P50 · FY2004 · CA
SPORE in Prostate Cancer$2,741,032
P50 · FY2003 · CA
SPORE in Prostate Cancer$2,471,062
P50 · FY2002 · CA
Developmental projects program$0
P50 · FY2002 · CA